Theriva Biologics (TOVX) shares surged 74.6% to $0.4252 on Thursday after the company announced the publication of Phase 1 clinical trial data for its lead drug candidate, VCN-01, in the journal Clinical Cancer Research. The study, conducted in patients with head and neck squamous cell carcinoma (HNSCC), showed encouraging survival and biomarker signals, capturing the attention of traders. However, the move is not tied to any drug approval or revenue generation, and significant risks remain.
The Phase 1 trial enrolled 20 adults with refractory or metastatic HNSCC who had progressed despite prior treatments, including anti-PD-(L)1 checkpoint inhibitors. Median overall survival was 10.3 months in a low-dose group, 15.5 months in a sequential low-dose group, and 17.3 months in a sequential high-dose group. These data points suggest that VCN-01, an oncolytic adenovirus designed to replicate within tumor cells and degrade the tumor stroma, may enhance the efficacy of immune checkpoint inhibitors like durvalumab (Imfinzi, from AstraZeneca).
Biomarker data from the trial also showed increases in PH20 enzyme levels after VCN-01 dosing, indicating intratumoral replication, and shifts in CD8, PD-1, and PD-L1 markers consistent with immune activation. These findings are important for investors as they support the mechanism of action that Theriva plans to test in larger studies. However, Phase 1 trials are primarily designed to assess safety and dosing, not to prove efficacy for regulatory approval.
Theriva's primary value driver remains its planned pivotal Phase 3 trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC). In May, the company reached an agreement with the FDA on key aspects of the trial design, which will use repeat VCN-01 dosing in combination with standard chemotherapy. Earlier Phase 2b results showed improvements in overall survival and progression-free survival compared to chemotherapy alone.
Despite today's rally, Theriva's balance sheet remains a significant risk. As of March 31, 2026, the company had $14.4 million in cash and cash equivalents, with a cash runway extending only into the first quarter of 2027. Management has expressed substantial doubt about the company's ability to continue as a going concern without additional capital. Furthermore, the potential for dilution looms large: Theriva may need to issue up to 16.2 million shares if outstanding warrants are exercised, adding to the current 45.9 million shares outstanding.
Investors should view today's price surge with caution. While the VCN-01 data in head-and-neck cancer provides a proof-of-concept for the drug's mechanism, the company still faces significant clinical, financial, and execution risks. The stock's gains are driven by early-stage data, and the path to approval—especially in pancreatic cancer—remains long and uncertain. Without near-term catalysts such as new financing or partnership deals, the rally may be short-lived.
